J&J, HHS sign expanded deal to find COVID-19 vaccine
Johnson & Johnson (J&J) unit Janssen has expanded an existing R&D agreement with the US Department of Health and Human Services ( HHS) as part of efforts to speed up the development of an investigational vaccine for the novel coronavirus COVID-19.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
26 November 2020 The US Department of Health and Human Services will reveal more information regarding its licensing of IP to private companies for drug development, it has confirmed in a letter to a congressional watchdog.
24 September 2020 Danish biotech Genmab has commenced binding arbitration of two matters with Janssen Biotech, a Johnson & Johnson company, over royalty payments for a cancer drug.
27 March 2020 A consortium of life sciences companies including Novartis, Bristol Myers Squibb and GSK have united to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19.